Skip to main content

Table 3 Adverse Events during the 12-Week Open-Label Treatment Phase

From: Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study

Adverse EventsPersistent PTH (n = 100)
All Events
  ≥ 1 Adverse Event78
  ≥ 1 Treatment-Related Adverse Event38
  ≥ 1 Serious Adverse Event0
 Any Adverse Event leading to Study Discontinuation2
Adverse Events occurring in ≥ 2% of Patientsa
 Injection-Site Reactions
  Pain7
  Erythema5
  Hemorrhage3
 Acid Reflux1
 Constipation30
 Diarrhea2
 Dizziness9
 Dry Mouth4
 Fatigue5
 Hot Flashes3
 Influenza2
 Irregular Menstruation3
 Low Back Pain2
 Nausea7
 Palpitations2
 Upper Abdominal Pain5
 Worsened Headache8
  1. Data are reported as number of patients. If a patient had the same adverse event more than once, it was counted only once
\